Results 241 to 250 of about 5,003 (295)

Operational procedure sharing pathway in veno-occlusive disease: a Delphi consensus-based recommendations. [PDF]

Front Oncol
Bonifazi F, Ravaioli F, Iori AP, Milone G, Olivieri A, Prete A, Russo D, Santarone S, Sica S, Zecca M, Colecchia A.   +10 more
europepmc   +1 more source

Acquired Amegakaryocytic Thrombocytopenia with Glycoprotein IIb/IIIa Antibody in a Patient with Mantle Cell Lymphoma. [PDF]

Intern Med
Sato K, Ueki T, Tokutake T, Ueno M, Ichikawa N, Sumi M, Kobayashi H.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Platelet transfusion: Alloimmunization and refractoriness

Seminars in Hematology, 2020
The transfusion of platelets for both prophylaxis and treatment of bleeding is relevant to all areas of medicine and surgery. Historically, guidance regarding platelet transfusion has been limited by a lack of good quality clinical trials and so has been based largely on expert opinion. In recent years however there has been renewed interest in methods
Michael F. Murphy, Michael F. Murphy, Catherine Prodger, Alexandros Rampotas, Simon J. Stanworth, Lise J Estcourt   +5 more
openaire   +3 more sources

Platelet transfusion refractoriness and anti‐HLA immunization

Transfusion, 2021
AbstractPlatelet transfusion refractoriness (PTR), defined as an unsatisfactory post‐transfusion platelet count increment, is a common complication of patients receiving multiple transfusions. Different strategies are described in the management of PTR. In this work, we demonstrate the efficacy of the detection and identification of anti‐HLA antibodies
Blandin, Lucie, Dougé, Aurore, Fayard, Amandine, Bay, Jacques‐olivier, Berlie, Guillaume, Pereira, Bruno, Lemal, Richard, Rouzaire, Paul   +7 more
openaire   +3 more sources

Causes of refractoriness to platelet transfusion

Current Opinion in Hematology, 1995
Platelet refractoriness is a multifactorial problem that often leads to aggressive measures in an attempt to treat a thrombocytopenic patient. Identification of the underlying causes should allow for prevention and management regimens to improve both transfusion practice and patient outcome.
Richard C. Friedberg, Paul D. Mintz
openaire   +3 more sources

The definition of refractoriness to platelet transfusions

Transfusion Medicine, 1992
SUMMARY. The relationship between the 1 and 20 h post‐transfusion platelet count and three parameters used to define refractory transfusions, namely the corrected increment (CI), platelet increment (PI), and percentage platelet recovery (%REC), was studied in 437 non‐HLA matched platelet transfusions given to 102 patients with bone marrow failure. The
M. M. Wolf, J. P. Matthews, J. F. Bishop, Jeff Szer, K. Yuen, K McGrath   +5 more
openaire   +3 more sources

Platelet transfusions: The problem of refractoriness

Blood Reviews, 1990
Refractoriness is a complication of multiple platelet transfusions in 30-70% of patients with bone marrow failure. The major causes are HLA alloimmunisation and non-immune platelet consumption; the latter is usually found in patients with DIC, septicaemia or splenomegaly.
M.F. Murphy, A.H. Waters
openaire   +3 more sources

Management of Patients Refractory to Platelet Transfusion

Journal of Infusion Nursing, 2007
This article discusses the causes and management of platelet refractoriness. Improvements in the quality of platelets and leukoreduction have reduced the morbidity and mortality related to alloimmunization and refractoriness of patients to platelet transfusion.
Ronald A. Sacher, Ronald A. Sacher, Porselvi Chockalingam   +2 more
openaire   +3 more sources

Antileukocyte Antibodies in Patients Refractory to Platelet Transfusions [PDF]

American Journal of Clinical Pathology, 1979
Sera from 12 multitransfused patients who were refractory to random-donor platelets were tested for lymphocytotoxic and leukoagglutinating antibodies using panel cells from various volunteers whose HLA-A and -B antigens were known. All sera contained leukoagglutinins reactive with cells from at least one panel member, whereas only 33% had ...
Bruce R. MacPherson, Robert G. Westphal
openaire   +2 more sources